Literature DB >> 25977120

Soluble ST2 and IL-33: Potential markers of endometriosis in the Tunisian population.

Maroua Mbarik1, Wajih Kaabachi2, Balkis Henidi3, Faycal Haj Sassi4, Kamel Hamzaoui5.   

Abstract

Interleukin-33 is an IL-1 family cytokine which signals via its T1/ST2 receptor, and acts as a key regulator of inflammation. This study aims to measure the expression of soluble ST2 (sST2) and IL-33 in endometriosis. We investigated thirty women with laparoscopic and histopathological confirmed endometriosis and 20 control women without pelvic pathology. Peripheral blood mononuclear cells and peritoneal fluid (PF) were assessed for sST2 and IL-33 levels that are measured by sandwich enzyme-linked immunosorbent assay. Peritoneal fluid IL-33 mRNA expression was quantified by real-time reverse transcription polymerase chain reaction assays. We found that IL-33 levels in PF and in serum were significantly higher in patients with endometriosis compared to women without endometriosis (P < 0.05). IL-33 increased levels were significantly more important in PF [10.45 ± 14.33 ng/mL] than in serum [2.68 ± 1.54 ng/mL] from endometriosis patients. Higher levels of IL-33 mRNA expression were detected in PF from patients with endometriosis. Soluble ST2 levels in PF were significantly different between patients [2.96 ± 0.98 ng/mL; P < 0.0001] and controls [0.88 ± 0.076 ng/mL]. Serum sST2 levels were similarly expressed in endometriosis patients and in controls (P > 0.05). Significant correlation was observed between IL-33 and sST2 levels in PF. In conclusion, IL-33 and sST2 values observed in PF were found to correlate with endometriosis severity. Elevated and correlated PF IL-33 and sST2 levels from patients with endometriosis suggested a potential role as surrogate markers of disease activity.
Copyright © 2015 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ELISA; Endometriosis; IL-33; Inflammation; RT-qPCR; Soluble ST2

Mesh:

Substances:

Year:  2015        PMID: 25977120     DOI: 10.1016/j.imlet.2015.05.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

1.  Interleukin-33 modulates inflammation in endometriosis.

Authors:  Jessica E Miller; Stephany P Monsanto; Soo Hyun Ahn; Kasra Khalaj; Asgerally T Fazleabas; Steven L Young; Bruce A Lessey; Madhuri Koti; Chandrakant Tayade
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

2.  Plasma High Mobility Group Box 1 (HMGB1), Osteopontin (OPN), and Hyaluronic Acid (HA) as Admissible Biomarkers for Endometriosis.

Authors:  Yunlei Cao; Xishi Liu; Sun-Wei Guo
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

3.  Platelets and Regulatory T Cells May Induce a Type 2 Immunity That Is Conducive to the Progression and Fibrogenesis of Endometriosis.

Authors:  Fengyi Xiao; Xishi Liu; Sun-Wei Guo
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

4.  Association of Inflammatory Markers/Cytokines with Cardiovascular Risk Manifestation in Patients with Endometriosis.

Authors:  Uzma Rafi; Shaaf Ahmad; Syeda Shazia Bokhari; Muhammad Amir Iqbal; Amna Zia; Muhammad Amjad Khan; Nabila Roohi
Journal:  Mediators Inflamm       Date:  2021-10-31       Impact factor: 4.711

5.  IL-33 activates group 2 innate lymphoid cell expansion and modulates endometriosis.

Authors:  Jessica E Miller; Harshavardhan Lingegowda; Lindsey K Symons; Olga Bougie; Steven L Young; Bruce A Lessey; Madhuri Koti; Chandrakant Tayade
Journal:  JCI Insight       Date:  2021-12-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.